KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Long-Term Deferred Tax: 2009-2010

  • Rigel Pharmaceuticals' Long-Term Deferred Tax fell 6.59% to $197.0 million in Q4 2010 from the same period last year, while for Dec 2010 it was $197.0 million, marking a year-over-year decrease of 6.59%. This contributed to the annual value of $197.0 million for FY2010, which is 6.59% down from last year.
  • Rigel Pharmaceuticals' Long-Term Deferred Tax amounted to $197.0 million in Q4 2010, which was down 6.59% from $210.9 million recorded in Q4 2009.
  • In the past 5 years, Rigel Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $210.9 million in Q4 2009 and a low of $197.0 million during Q4 2010.
  • For the 2-year period, Rigel Pharmaceuticals' Long-Term Deferred Tax averaged around $204.0 million, with its median value being $204.0 million (2009).
  • Data for Rigel Pharmaceuticals' Long-Term Deferred Tax shows a maximum YoY decreased of 6.59% (in 2010) over the last 5 years.
  • Quarterly analysis of 2 years shows Rigel Pharmaceuticals' Long-Term Deferred Tax stood at $210.9 million in 2009, then decreased by 6.59% to $197.0 million in 2010.